Global EditionASIA 中文雙語Fran?ais
    World
    Home / World / China-Europe

    Merck announces collaboration with Xi'an Janssen to launch INVOKANA

    chinadaily.com.cn | Updated: 2018-07-15 10:54
    Share
    Share - WeChat

    Merck, a leading science and technology company, on Friday signed an agreement with Xi'an Janssen Pharmaceuticals Ltd. in Beijing, to launch INVOKANA, an innovative drug for adults with type 2 diabetes.

    "Our mission is to transform 40 million patients' lives in China by 2025. We are very pleased to be collaborating with Xi'an Janssen, who shares our goal of helping improve the lives of people living with or at risk of type 2 diabetes. Merck has been making continued efforts to expand its portfolio with the aim of providing more high-quality medicines and better treatment options for millions of diabetic patients in China. The introduction of INVOKANA® to China reinforces our long-term commitment to China,"said Rogier Janssens, Managing Director and General Manager of Merck's biopharma business in China.

    Through this agreement, the two companies will work closely together on future development, distribution, promotion, access, marketing and sales of INVOKANA in the country and Merck will hold the exclusive rights for INVOKANA's promotion in China.

    INVOKANA is a member of a novel class of drugs known as sodium-glucose co-transporter 2 inhibitor and was approved in China in September 2017. INVOKANA is approved for treatment of type 2 diabetes in combination with metformin or with metformin plus sulfonylurea in adults who have not achieved adequate glycaemic control on these oral therapies.

    With a mechanism of action that is independent of insulin secretion and sensitivity, INVOKANA helps reduce the reabsorption of filtered glucose in the kidneys and lowers the renal threshold for glucose and thereby increases urinary glucose excretion through inhibition of highly selective SGLT-2.

    Besides its pronounced anti-hyperglycemic effects, INVOKANA can also bring additional benefits to patients such as reductions in body weight, slowing the progression in albuminuria and lowering of blood pressure . By adding INVOKANA, another novel therapy following Glucophage, and other diabetes' products, to its diabetes portfolio, Merck is committed to providing Chinese patients with better treatment options for their diabetes and complications, leading to better quality of life.

    According to the 2017 International Diabetes Federation Diabetes Atlas, China has more than 114 million people living with diabetes, the largest number of any country in the world. Additionally, data from the China Guideline for the Prevention of Type 2 Diabetes (2017 Edition) shows that in China the prevalence of type 2 diabetes among the adult population is 10.4%. Research also shows that the number of people with diabetes is rising year on year, with patients often being diagnosed at a younger age and many still struggling to control their blood sugar level. Indeed, approximately half of adults with the disease do not achieve recommended levels of glucose control , which increases the risk of potentially life-threatening complications, such as heart disease, stroke, renal failure, and diabetic retinopathy.

    Under the Healthy China 2030 Initiative, health of the Chinese people has been given strategic importance. The Chinese government has gradually introduced a shift of focus from disease treatment to disease prevention.

    "With poor lifestyle choices, particularly in relation to exercise and diet, the number of diabetic patients is increasing rapidly all over the world. More effective treatment options are needed to help diabetic patients control the disease and improve their overall quality of life”, said Ji Linong, a professor from Peking University People's Hospital and chairman of the International Diabetes Federation Western Pacific Region, speaking at the signing ceremony. Prof. Ji also emphasized the importance of seeking medical advice at certified hospitals as well as early diagnosis and early intervention to improve treatment outcomes. He highlighted that healthy diet and lifestyle change are an important way to help prevent diabetes.

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    无码H肉动漫在线观看| 天堂最新版中文网| 精品久久久久久无码中文野结衣| 无码国产色欲XXXXX视频| 少妇人妻88久久中文字幕| 无码无套少妇毛多18PXXXX| 免费中文字幕视频| 在线看福利中文影院| 精品欧洲av无码一区二区| 无码人妻丝袜在线视频| 最近免费字幕中文大全| 久久精品无码免费不卡| 性无码专区无码片| 日韩精品无码一区二区视频| 人妻中文字幕无码专区| 无码免费又爽又高潮喷水的视频 | 精品久久久无码中文字幕天天| 欧日韩国产无码专区| 日韩精品久久无码人妻中文字幕 | 国产成人A亚洲精V品无码 | 痴汉中文字幕视频一区| 无码精品第一页| 免费无码VA一区二区三区| 久久久久精品国产亚洲AV无码| 久草中文在线观看| 久久有码中文字幕| 国产欧美日韩中文字幕 | а中文在线天堂| 18禁网站免费无遮挡无码中文| 亚洲欧美日韩中文播放| 亚洲Av无码国产情品久久| 国产V片在线播放免费无码| 国产在线拍揄自揄拍无码| 午夜不卡久久精品无码免费| 亚洲av无码一区二区三区不卡| 亚洲永久无码3D动漫一区| 在线精品无码字幕无码AV| 亚洲精品中文字幕无码蜜桃| 亚洲av无码精品网站| 日韩精品无码一区二区三区不卡 | 狠狠躁天天躁无码中文字幕|